β-Diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 1, 2005, Pages 111-120

  Dayam, Raveendra ^a   Sanchez, Tino ^a   Clement, Omoshile ^b   Shoemaker, Robert ^c   Sei, Shizuko ^d   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ACCELRYS INC   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; INTEGRASE INHIBITOR; RHODANINE; SALICYLIC ACID; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FURANS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RHODANINE; SALICYLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TRIAZOLES;

EID: 12144254795     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0496077     Document Type: Article

References (50)

1. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
2. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discovery 2002, 1, 13-25.
3. Brown, P. O. Integration. In Retroviruses; Coffin, J. C., Hughes, S. H., Varmus, H. E., Eds.; Cold Spring Harbor Press: Plainview, NY, 1999
4. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
5. Neamati, N. Structure-based HIV-1 integrase inhibitor design: A future perspective. Expert Opin. Invest Drugs 2001, 10, 281-296.
6. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: A ten-year saga. Expert Opin. Ther. Pat. 2002, 12, 709-724.
7. Dayam, R.; Neamati, N. Small-Molecule HIV-1 Integrase Inhibitors: The 2001-2002 Update. Curr. Pharm. Des. 2003, 9, 1789-1802.
8. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A.; Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
9. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. in Vitro Activity of a New HIV-1 Integrase Inhibitor in Clinical Development. 9th Conference on retroviruses and opportunistic infections, Seattle, WA, 2002.
10. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 2003, 4, 206-209.
11. Guner, O. F. Pharmacophore perception, development, and use in drug design; International University Line: La Jolla, CA, 2000.
12. Patel, Y.; Gillet, V. J.; Bravi, G.; Leach, A. R. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comput. Aided Mol. Des. 2002, 16, 653-681.
13. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
14. Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Wendoloski, J. J.; Ashwell, S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962-1968.
15. Lengauer, T.; Lemmen, C.; Rarey, M.; Zimmermann, M. Novel technologies for virtual screening. Drug Discovery Today 2004, 9, 27-34.
16. Dror, O.; Shulman-Peleg, A.; Nussinov, R.; Wolfson, H. J. Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr. Med. Chem. 2004, 11, 71-90.
17. Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Lewi, P.; Vinkers, M. H.; Janssen, P. A. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins 2004, 54, 526-533.
18. van Drie, J. H. Pharmacophore discovery - lessons learned. Curr. Pharm. Des. 2003, 9, 1649-1664.
19. Langer, T.; Krovat, E. M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discovery Devel. 2003, 6, 370-376.
20. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
21. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
22. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
23. Hong, H.; Neamati, N.; Winslow, H. E.; Christensen, J. L.; Orr, A.; Pommier, Y.; Milne, G. W. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir. Chem. Chemother. 1998, 9, 461-472.
24. Neamati, N.; Hong, H.; Sunder, S.; Milne, G. W.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: Identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
25. Carlson, H. A.; Masukawa, K. M.; Rubins, K.; Bushman, F. D.; Jorgensen, W. L.; Lins, R. D.; Briggs, J. M.; McCammon, J. A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
26. Mustata, G. I.; Brigo, A.; Briggs, J. M. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1447-1454.
27. Herr, R. J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry and synthetic methods. Bioorg. Med. Chem. 2002, 10, 3379-3393.
28. Shionogi & Co Ltd. Indole derivatives with antiviral activity. WO9950245-A, 1999.
29. Shionogi & Co Ltd. Integrase inhibitors containing aromatic heterocycle derivatives. WO0117968-A, 2001.
30. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
31. Sechi, M.; Derudas, M.; Dallocchio, R.; Dessi, A.; Bacchi, A.; Sannia, L.; Carta, F.; Palomba, M.; Ragab, O.; Chan, C.; Shoemaker, R.; Sei, S.; Neamati, N. Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors. J. Med. Chem. 2004, 47, 5298-5310.
32. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
34. Habib, N. S.; Soliman, R.; Ashour, F. A.; el-Taiebi, M. Synthesis and antimicrobial testing of novel oxadiazolylbenzimidazole derivatives. Pharmazie 1997, 52, 746-749.
35. Takasu, K.; Inoue, H.; Kim, H. S.; Suzuki, M.; Shishido, T.; Wataya, Y.; Ihara, M. Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity. J. Med. Chem. 2002, 45, 995-998.
36. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Fujiwara, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: Thiazolidine derivatives. Biochem. Biophys. Res. Commun. 1997, 238, 643-647.
37. Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther. 1984, 229, 226-230.
38. El-Kabbani, O.; Ruiz, P.; Darmanin, C.; Chung, R. P. Aldose reductase structures: Implications for mechanism and inhibition. Cell Mol. Life Sci. 2004, 61, 750-762.
39. Cheng, A.; Diller, D. J.; Dixon, S. L.; Egan, W. J.; Lauri, G.; Merz, K. M., Jr. Computation of the physio-chemical properties and data mining of large molecular collections. J. Comput. Chem. 2002, 23, 172-183.
40. Egan, W. J.; Walters, W. P.; Murcko, M. A. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discovery Dev. 2002, 5, 540-549.
41. Egan, W. J.; Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 2002, 54, 273-289.
42. Long, Y. Q.; Jiang, X. H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N. Rational Design and Synthesis of Novel Dimeric Diketoacid-Containing Inhibitors of HIV-1 Integrase: Implication for Binding to Two Metal Ions on the Active Site of Integrase. J. Med. Chem. 2004, 47, 2561-2573.
43. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of conformational coverage. 2. application of conformational models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-304.
44. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of conformational coverage 0.1. validation and estimation of coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
45. Smellie, A.; Teig, S. L.; Towbin, P. Poling - Promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
46. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
47. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
48. CCDC, C. C. E., UK GOLD; 1.2 ed.
49. Nissink, J. W.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002, 49, 457-471.
50. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.